PYC Stock Overview
PYC Therapeutics Limited, a drug-development company, engages in the discovery and development of drug solutions in the areas of ribonucleic acid therapeutics in Australia.
Notes are coming soon
PYC Therapeutics Limited Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$0.072|
|52 Week High||AU$0.13|
|52 Week Low||AU$0.057|
|1 Month Change||9.09%|
|3 Month Change||-10.00%|
|1 Year Change||-40.00%|
|3 Year Change||16.13%|
|5 Year Change||148.28%|
|Change since IPO||-72.31%|
Recent News & Updates
Here's Why We're Watching PYC Therapeutics' (ASX:PYC) Cash Burn SituationJan 25
Companies Like PYC Therapeutics (ASX:PYC) Are In A Position To Invest In GrowthJul 31
We're Not Very Worried About PYC Therapeutics' (ASX:PYC) Cash Burn RateMar 28
Non-Executive Chair of the Board Alan Tribe Just Bought A Handful Of Shares In PYC Therapeutics Limited (ASX:PYC)Feb 20
Have Insiders Been Selling PYC Therapeutics Limited (ASX:PYC) Shares?Jan 26
What You Need To Know About PYC Therapeutics Limited's (ASX:PYC) Investor CompositionDec 22
We Think PYC Therapeutics (ASX:PYC) Can Easily Afford To Drive Business GrowthNov 17
|PYC||AU Biotechs||AU Market|
Return vs Industry: PYC underperformed the Australian Biotechs industry which returned 16.4% over the past year.
Return vs Market: PYC underperformed the Australian Market which returned 0.4% over the past year.
|PYC Average Weekly Movement||9.6%|
|Biotechs Industry Average Movement||8.9%|
|Market Average Movement||8.4%|
|10% most volatile stocks in AU Market||15.5%|
|10% least volatile stocks in AU Market||3.4%|
Stable Share Price: PYC is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 10% a week.
Volatility Over Time: PYC's weekly volatility (10%) has been stable over the past year.
About the Company
PYC Therapeutics Limited, a drug-development company, engages in the discovery and development of drug solutions in the areas of ribonucleic acid therapeutics in Australia. The company’s preclinical development programs include VP-001, drug program for retinitis pigmentosa type 11; and PYC-001, a drug program for the treatment of autosomal dominant optic atrophy. It also focuses on the development of programs for kidney, retinal, and central nervous system diseases.
PYC Therapeutics Limited Fundamentals Summary
|PYC fundamental statistics|
Is PYC overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|PYC income statement (TTM)|
|Cost of Revenue||AU$0|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.0044|
|Net Profit Margin||-86.41%|
How did PYC perform over the long term?See historical performance and comparison